Table S1. PANAS mean values completed before drug administration sessions 1–4. Table S2. 5D-ASC F table. Figure S1. Effects of LSD on DASS scores during screening (white bars), session 1 (S1; light gray), and session 5 (S5; dark gray) on the depression scale (A) anxiety scale (B), stress scale (C), and total DASS score (D). Bars depict mean scores ± SEM. Figure S2. Effects of LSD on the Addiction Research Inventory (ARCI) PCAG - chlorpromazine-alcohol group scale (A), and BG – benzedrine group scale (B) on sessions 1–4. Bars depict mean peak change scores ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S3. Effects of LSD on ratings of “like drug” (A), “dislike drug” (B), and “want more drug” (C) on sessions 1–4. Bars depict mean peak change scores ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S4. Effects of LSD on the Profile of Mood States (POMS) scales of anger (A), anxiety (B), depression (C), confusion (D), elation (E), fatigue (F), and friendliness (G) on sessions 1–4. Bars depict mean peak change scores ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S5. Effects of LSD during sessions 1 (white bars) and 4 (striped bars) on Emotional images task – positive images (A) negative images (B), and the cyberball task during the acceptance phase (C). Bars depict mean ratings or scores ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S6. Effects of LSD during sessions 1 (white bars) and 4 (striped bars) on the n-back task for 2-back (A) for 3-back (B), and the digital symbol substitution (DSST) task (C). Bars depict mean correct (d') for n-back tasks and mean number correct for DSST ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S7. Effects of LSD during sessions 1 (white bars) and 4 (striped bars) on hit rates during the emotional faces task for anger (A), disgust (B), fear (C), happy (D), sad (E), and surprise (F). Bars depict mean hit rate scores ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S8. Effects of LSD during session 5 on the emotional faces task (A) for the emotional images task – positive images (B), and negative images (C). Bars depict mean hit rates for the emotional faces task and mean ratings for the emotional images task ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S9. Effects of LSD during session 5 on the n-back task for the 2-back condition (A) and for the 3-back condition (B), and the digital symbol substitution (DSST) task (C). Bars depict mean correct (d') for n-back tasks and mean number correct for DSST ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns. Figure S10. Effects of LSD during session 5 on the Cyberball task for the acceptance phase (A) and for the rejection phase (B) Bars depict mean mood scores ± SEM. No significance between 26 μg vs. placebo or 13 μg vs. placebo, ns.